Loading…
Indo Count Industries Ltd
NSE: ICIL BSE: 521016 INE483B01026 Consumer Discretionary Consumer 🔎 Screen
Microcap 250
₹8,449 Cr
Market Cap
66.1
P/E
PEG
8.2%
ROCE
5.5%
ROE
0.57
D/E
9.8%
OPM
-8.0%
% from 52W High
97
α RS
⚖️ Compare 🔒 Generate Report 📚 Guides
📈 Price History
Ratio Health
Excellent
Good
Average
Poor
By Category
Shareholding
About

Indo Count Industries Limited (ICIL) is engaged in the home textiles & bedding industry. The company is a manufacturer and exporter of bed sheets, bed linen and quilts. It is the largest global bed linen player.

✓ Strengths 1
  • Company has been maintaining a healthy dividend payout of 17.4%
! Concerns 3
  • Stock is trading at 3.62 times its book value
  • The company has delivered a poor sales growth of 10.4% over past five years.
  • Company has a low return on equity of 11.2% over last 3 years.
Key Ratios Snapshot
📊 Sector Averages
📈 Growth Pattern
📊 Quick Scorecard
Loading…
🔒
Premium Feature
AI-generated 10-section company profile — business model, financials, strengths, risks & management quality
Upgrade to Premium
Already a member? Log in
📐
3-Statement Financial Model
Bear / Base / Bull projections · DCF fair value · Reverse-DCF
Open Model →
Mixed quarter: revenue grew 5.8% YoY to ₹1,088 Cr, driven by new businesses, but core business volume declined low-teens and PAT was flat QoQ at ₹24 Cr due to higher depreciation and interest from US investments. quarter Investor Presentation One-Pager? Jun 2026
Revenue
₹1,088 Cr
+5.8% YoY; new businesses doubled to ~$90M annualized run-rate
EBITDA Margin
10.7%
+140bps YoY; recovery from 9.5% in Q3 FY26, but still below FY25 full-year margin of 13.8%
PAT
₹24 Cr
+15% YoY, but -0.9% QoQ; flow-through constrained by higher depreciation (₹43 Cr) and finance costs (₹44 Cr)
Volume (Mn Mtrs)
20.5
-13% QoQ; full-year volume 94.1 Mn, down 12% from FY25's 106.4 Mn; core business protected market share but lost volumes
What Went Right
  • New businesses (Utility Bedding + USA Brands) revenue scaled to ₹792 Cr in FY26, up ~2.8x from ₹285 Cr in FY25; Q4 alone contributed ₹270 Cr, up 49% QoQ.
  • EBITDA margin expanded QoQ to 10.7% from 9.5%, driven by better product mix, fixed-cost absorption in new US plants, and favourable exchange rates.
  • No loss of any customer or order despite US tariff volatility; management maintained market share in core bed linen.
  • ESG S&P Global score jumped from 45 to 78 over two years, now top 3 percentile globally in Textiles, Apparel & Luxury Goods.
  • Net debt/equity remained manageable at 0.32x; operating cash flow was strong at ₹573 Cr in FY26 (vs ₹394 Cr in FY25).
What to Watch
  • Core business revenue fell low-teens in FY26 due to US tariff uncertainty, with volumes dropping 12% to 94.1 Mn meters from 106.4 Mn in FY25.
  • Full-year EBITDA margin dropped sharply to 11.0% from 13.8% in FY25, reflecting tariff sharing with customers, incubation costs in new businesses, and under-absorption of fixed costs.
  • PAT halved to ₹127 Cr in FY26 (vs ₹250 Cr in FY25) as higher depreciation (₹292 Cr vs ₹215 Cr) and finance costs weighed; Q4 PAT flat QoQ despite EBITDA growth.
  • Q4 volume declined 13% QoQ to 20.5 Mn meters, indicating sustained softness in the core business; sequential recovery remains uncertain.
  • Macro environment remains volatile: US tariff levels fluctuated from 10% to 50% and back to 10% during FY26, and West Asia conflict poses additional risk.
Management Guidance
  • Target ~30%+ revenue growth in FY27 to ~₹5,500 Cr with ~13% EBITDA margin.
  • Core business expected to grow >16% to ~₹4,000 Cr; new businesses to double to ~₹1,500 Cr.
  • Incremental revenue addition of ~₹1,300 Cr in FY27 – a record for the company.
  • Reaffirmed aspiration to double revenue by 2028 over FY25 base, with brands and utility bedding contributing ~$275M (vs $90M in FY26).
  • Full-year FY27 volume target of 105-110 Mn meters (up from 94.1 Mn in FY26).
Investor Lens
The investment thesis rests on ICIL's transformation from a pure bed linen exporter to a multi-category, brand-led home textile player with on-shore US manufacturing. Q4 FY26 showed progress: new businesses reached $90M annualized run-rate and EBITDA margins recovered QoQ. However, core business volumes continue to decline and full-year profitability (EBITDA margin 11%, PAT halved) remains weak. The FY27 guidance of ₹5,500 Cr revenue and 13% EBITDA margin is ambitious, implying a sharp V-shaped recovery. Investors should watch: (1) US tariff clarity and order momentum, (2) ramp-up of the three US plants (currently ~65% utilization), (3) debt reduction trajectory, and (4) whether new brand/license revenues (Wamsutta, Tommy Hilfiger) can drive sufficient mix shift to offset core weakness.
From investor presentation · AI-generated analysis · Not investment advice
🔒
Premium Feature
Investor Presentation One-Pager — quarterly highlights, what went right/wrong & management guidance
Upgrade to Premium
Already a member? Log in
📊 MIXED Revenue up 3%, but OPM slips to 8%; PAT up 14% aided by other income.
Revenue
Revenue stood at ₹1,058 Cr, marginally up 3.4% year-on-year but flat (-0.5%) sequentially. The modest YoY growth indicates subdued demand traction.
Profitability
Net profit rose 14.3% YoY to ₹24 Cr, supported by a sharp increase in other income (₹30 Cr). EPS improved to ₹1.22 from ₹1.06 in the year-ago quarter.
Margins
Operating profit margin contracted to 8% from 9% both YoY and QoQ, reflecting cost pressure. The absolute operating profit fell 4.4% YoY despite revenue growth.
Cash Flow
No cash flow data provided for this period.
Balance Sheet
Total borrowings stood at ₹1,342 Cr against reserves of ₹2,316 Cr, resulting in a debt-to-equity ratio of 0.54. The high absolute debt level remains a monitorable.
Key Risks
High PE ratio of 54.4 implies stretched valuation relative to earnings. Margin compression and elevated borrowings (~₹1,342 Cr) pose profitability and interest cost risks.
Outlook
Sustained volume growth is essential to reverse margin decline. Interest cost and debt management will be critical for future profitability.
Generated by AI · Mar 2026 results · Not investment advice
🔒
Free Account Required

Create a free Finmagine account to access Finmagine™ Scorecard.

See how this company scores across 5 dimensions — Financial Health, Growth Prospects, Competitive Position, Management Quality, and Valuation — powered by 30+ computed ratios.

Create Free AccountLog In
🔒
Premium Feature

Upgrade to Finmagine Premium to unlock Ask AI.

Get 25 expert AI analysis templates — Business KPIs, Comprehensive, Forensic Governance, Peer Comparison, Risk-Reward, Full Research Report, IPO Decoder, Red Flag Detector, and more — ready to paste into ChatGPT, Claude, Gemini, or Perplexity.

Upgrade to PremiumCreate Free Account
🔒
Premium Feature

Upgrade to Finmagine Premium to unlock Peer Comparison.

Compare this company side-by-side against its sector peers with financial metrics, ratio benchmarking, and relative performance across all key dimensions.

Upgrade to PremiumCreate Free Account
🔒
Premium Feature

Upgrade to Finmagine Premium to unlock Documents.

Access concall transcripts, annual reports, credit ratings, and investor presentations.

Upgrade to PremiumCreate Free Account

📊 Sector KPIs

Industry-specific KPIs with historical trend — AI-extracted from investor presentations
🔒
Premium Feature
Industry-specific KPIs with historical trend across quarters — AI-extracted from investor presentations
Upgrade to Premium
Already a member? Log in

💼 Management Guidance

Revenue, loan book, NIM and other management targets — with hit/miss tracking
🔒
Premium Feature
Management guidance targets with historical hit/miss tracking — unlocked with Premium
Upgrade to Premium
Already a member? Log in

🎯 Thesis Tracker

Guidance vs Delivery — management track record
🔒
Premium Feature
Management guidance vs actual delivery — track whether revenue & PAT targets were Beat, Met or Missed across every reporting year
Upgrade to Premium
Already a member? Log in
🔒
Premium Feature

Upgrade to Finmagine Premium to unlock Full Report.

Read the complete Finmagine™ investment research report — comprehensive fundamental analysis, business model assessment, competitive positioning, and investment recommendation.

Upgrade to PremiumCreate Free Account

📊 Analysis Methodology

This comprehensive investment analysis was conducted using The Finmagine™ Stock Analysis & Ranking Methodology, a proprietary framework that systematically evaluates stocks across five critical dimensions: Financial Health, Growth Prospects, Competitive Positioning, Management Quality, and Valuation.

🎯
Discover Our Proven Investment Framework Learn how we analyze and rank stocks using advanced quantitative models, multi-dimensional scoring systems, and dynamic discriminatory ranking techniques that have guided successful investment decisions across market cycles.
📊 Explore The Finmagine™ Methodology

A comprehensive, bias-free framework for analyzing and ranking stocks by Financial Strength, Growth Potential, Competitive Edge, Management Quality, and Value.

⚠️ Important Disclaimers — Please read without fail.

Investment Risk:
Investing in securities, including equities and mutual funds, involves inherent risks, including the potential loss of principal. All investments are subject to market fluctuations, regulatory changes, and other risks that may affect their value. Past performance is not indicative of future results. This report is provided for informational and educational purposes only and should not be construed as investment advice under any circumstances.

No Investment Recommendation:
This report does not constitute, nor should it be interpreted as, an offer, solicitation, or recommendation to buy, sell, or hold any securities or financial products. Investors are strongly advised to conduct their own independent research and due diligence and to consult with a SEBI-registered investment adviser or other qualified financial professional before making any investment decisions, taking into account their individual financial situation, risk tolerance, and investment objectives.

Conflict of Interest Disclosure:
The author and/or analyst may currently hold or have previously held positions in the securities or financial instruments discussed in this report. Any such positions, if material, are disclosed to the best of the author's knowledge and are not intended to influence the objectivity or independence of the analysis. This research is produced independently and is not sponsored, endorsed, or commissioned by any company, institution, or third party.

Information Sources:
The analysis and opinions expressed herein are based on publicly available information, including but not limited to company filings with the BSE/NSE, annual reports, management commentary, investor presentations, data from the Reserve Bank of India (RBI), SEBI, industry publications, and other reliable financial data sources. Information is believed to be accurate as of the date of publication but may be subject to change without notice. Readers are encouraged to independently verify all information before acting upon it.

Forward-Looking Statements:
This report may contain forward-looking statements, forecasts, or projections that are inherently subject to risks, uncertainties, and assumptions. Actual results may differ materially from those expressed or implied. The author does not undertake any obligation to update such statements in the future.

Regulatory Compliance:
This report is intended to comply with the Securities and Exchange Board of India (Research Analysts) Regulations, 2014, as amended, and other applicable Indian laws and regulations.

Limitation of Liability:
The content of this report is provided "as is" without any warranties, express or implied, including accuracy, completeness, merchantability, or fitness for a particular purpose. The author and publisher expressly disclaim any liability for errors, omissions, or any losses incurred as a result of reliance on the information provided. Readers assume full responsibility for their investment decisions.